Biocardia stock.

The estimated Net Worth of Peter Altman is at least $883 Thousand dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $205,985 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer, and Director at BioCardia.Nov 16, 2023 · SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ... BioCardia Inc (BCDA) stock is trading at $0.88 as of 9:36 AM on Thursday, Nov 16, a loss of -$0.07, or -6.91% from the previous closing price of $0.95. The stock has traded between $0.84 and $0.89 so far today. Volume today is light. So far 173,359 shares have traded compared to average volume of 4,872,239 shares.BioCardia, Inc. Common Stock (BCDA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

8 Nov 2023 ... Stock name: BCDA, Stock Code: BCDA, Company: BioCardia, Inc., Sector: Healthcare.8 Nov 2023 ... Stock name: BCDA, Stock Code: BCDA, Company: BioCardia, Inc., Sector: Healthcare.

SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...

BCDA Stock Shows Promising Performance with Potential 863.86% Increase: Analysts Recommend Buying BioCardia Inc. BCDA stock has shown promising performance on November 7, 2023, according to data sourced from CNN Money. The median target price is $4.00, indicating a potential increase of 863.86% from the last recorded price of $0.42.5 Sep 2023 ... Biocardia stock dropped from about $2 on July 21 to $1.10 on July 24, when the concerns of the DSMB were first revealed. After drifting down ...The estimated Net Worth of Peter Altman is at least $849 Tausend dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $171,654 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer und Director at BioCardia.BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 26.09% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Richard has made over 43 trades of the BioCardia stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of BCDA stock worth $14,600 on 17 June 2019.

Nov 8, 2023 · As of November 6, BioCardia’s shares were trading at $0.405. Over the past 52 weeks, the stock has experienced a significant decline of 78.11%. While BioCardia has achieved an average annual earnings growth rate of 3.7%, the Biotechs industry has seen earnings grow at a much higher rate of 21.9% annually. To stay updated on all of BioCardia ...

Convert Biocardia Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Select a stock. apple. wise. Select a currency. USD. NASDAQ: Biocardia Inc ( BCDA) = 0.71 USD. Provided by Alpha Vantage.

BioCardia, Inc. reports earnings inline with expectations. Reported EPS is $-0.12 EPS, expectations were $-0.12. Operator: Ladies and gentlemen, thank you for standing by and welcome to the ...BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 17d Why Beyond Air Shares Are Trading Lower By Around 37%?What this means: Biocardia Inc (BCDA) gets an Overall Rank of 53, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value.BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules (GlobeNewswire) -15.27% Nov-15-23 …Nov 29, 2023 · BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 18d Why Beyond Air Shares Are Trading Lower By Around 37%? BioCardia ( NASDAQ: BCDA) shares jumped over +105% premarket on Tuesday after the biotech firm received FDA approval for the Phase 3 clinical trial of its CardiAMP autologous cell therapy for the ...Sep 6, 2023 · SUNNYVALE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioCardia ®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...

According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.BioCardia (BCDA) In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on BioCardia, with a price target of $4.00 . The company’s shares closed last Tuesday ...Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods that may have been lost or stolen.Dec 1, 2023 · Earnings for BioCardia are expected to decrease in the coming year, from ($0.54) to ($0.56) per share. BioCardia has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 3rd, 2024 based off prior year's report dates. Read More. Biocardia. stock was originally listed at a price of $1,738.17 in Dec 31, 1997. If you had invested in Biocardia stock at $1,738.17, your return over the last 25 years would have been -99.96%, for an annualized return of -27.08% (not including any dividends or dividend reinvestments).

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules (GlobeNewswire)-15.27%. Nov-15-23 11:04AM BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study (Zacks ... BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of …

Mr. Fernandez BCDA stock SEC Form 4 insiders trading. Fernando has made over 1 trades of the BioCardia stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 14,277 units of BCDA stock worth $5,711 on 13 January 2018.14,277 units of BCDA stock worth $5,711 on 13 January 2018.Simon Stertzer owns over 166,666 units of BioCardia stock worth over $1,450,986 and over the last 7 years he sold BCDA stock worth over $0. In addition, he makes $76,250 as Independent Chairman of the Board at BioCardia. Wallmine is a radically better financial terminal. Sign up in seconds, it's free!GlobeNewswire News Room — BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules Funding Round • Nov 16, 2023 Artifact Lab raised $2,000,000 / Pre Seed from Cypher Capital and 4 other investorsNov 30, 2023 · BioCardia, Inc. (NASDAQ:BCDA) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.05. The business had revenue of $0.82 million for the quarter, compared to analysts' expectations of $0.04 million. Jul 24, 2023 · July 24, 2023. SUNNYVALE, Calif. – BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase III pivotal CardiAMP ... Source. Headline. Genocea Biosciences (NASDAQ:GNCAQ) vs. BioCardia (NASDAQ:BCDA) Financial Analysis. americanbankingnews.com - November 17 at 1:30 AM. BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. finance.yahoo.com - November 16 at 3:00 PM.Nov 15, 2023 · BioCardia (NASDAQ:BCDA) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better investment?We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability, media sentiment, risk and valuation. BioCardia : FORM OF SECURITIES PURCHASE AGREEMENT - Form 8-K Nov. 16: PU BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules Nov. 16: AQ The estimated Net Worth of Richard M Krasno is at least $411 Thousand dollars as of 17 June 2019. Mr. Krasno owns over 20,000 units of BioCardia stock worth over $140,700 and over the last 16 years he sold BCDA stock worth over $0. In addition, he makes $269,814 as Independent Director at BioCardia.

Nov 14, 2023 · SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...

Richard has made over 43 trades of the BioCardia stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of BCDA stock worth $14,600 on 17 June 2019.

2023 BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval 16 Nov 2023 BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules The FDA approved BioCardia Inc's (NASDAQ: BCDA) Phase 3 CardiAMP Heart Failure II study protocol of CardiAMP autologous cell therapy for ischemic heart failure. The currently ongoing CardiAMP ...Stock screener. Filter, compare, and track stocks. Insiders trading. See how executives trade. Heat map. Visualize ratios & metrics. Histogram. See ratios across industries. ... As the Vice President - Operations of BioCardia, the total compensation of Phil Pesta at BioCardia is $276,000.A high-level overview of BioCardia, Inc. (BCDA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.BioCardia Inc. Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings ... Sep 5, 2023 · SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- BioCardia ®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ... David has made over 5 trades of the BioCardia stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 1,600 units of BCDA stock worth $4,096 on 5 November 2018.Discover historical prices for ME stock on Yahoo Finance. View daily, weekly or monthly format back to when 23andMe Holding Co. stock was issued.About BioCardia® BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP™ autologous and NK1R+ allogeneic cell therapies are the Company’s biotherapeutic platforms that enable four product candidates in development.

Stock Price Forecast. The 1 analysts offering 12-month price forecasts for BioCardia Inc have a median target of 4.00, with a high estimate of 4.00 and a low estimate of 4.00. The median estimate ...Biocardia Inc stock performance at a glance. Check Biocardia Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.The estimated Net Worth of Simon H Stertzer is at least $1.35 Millón dollars as of 5 July 2019. Simon Stertzer owns over 166,666 units of BioCardia stock worth over $1,277,638 and over the last 7 years he sold BCDA stock worth over $0. In addition, he makes $76,250 as Independent Chairman of the Board at BioCardia.SAN CARLOS, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for ...Instagram:https://instagram. nasdaq pgenashr etfhow much is a jfk half dollar worthbest screeners for day trading Nov 14, 2023 · SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ... budlight atockbooks about business law Jul 24, 2023 · July 24, 2023. SUNNYVALE, Calif. – BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase III pivotal CardiAMP ... BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq ... cowz etf holdings BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules (GlobeNewswire)-15.27%. Nov-15-23 11:04AM BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study (Zacks ... BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of …BioCardia BCDA is set to give its latest quarterly earnings report on Wednesday, 2023-11-08. ... Stock Performance. Shares of BioCardia were trading at $0.405 as of November 06.The estimated Net Worth of Simon H Stertzer is at least 1.48 百万$ dollars as of 5 July 2019. Simon Stertzer owns over 166,666 units of BioCardia stock worth over 1,399,623$ and over the last 6 years he sold BCDA stock worth over 0$. In addition, he makes 76,250$ as Independent Chairman of the Board at BioCardia.